Project Grant R01AG095381
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant of $804,450 under the Aging Research program (CFDA 93.866) effective June 1, 2025, through March 31, 2030. This award supports scientific research investigating the mechanisms by which Apolipoprotein E4 (APOE4), a major genetic risk factor for Alzheimer's disease (AD), drives pathogenesis through neuronal dysfunction and network hyperexcitability. The research will...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $2.59 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with completion targeted for August 31, 2029. The grant funds fundamental research to elucidate mechanisms of adipocyte-brain communication and their impact on glial function, neuroprotection, and brain aging, with potential implications for preventing dementia and age-related...
- Federal Grant Award Summary The National Institute on Aging awarded a $2.22 million Project Grant to the University of California, Irvine under the Aging Research program (CFDA 93.866) for the period September 1, 2025 through August 31, 2027. This award supports the development and optimization of enhancer adeno-associated virus (AAV) vectors—genetically engineered viral tools designed to provide cell-type-specific genetic access and manipulation capabilities in the brain. The primary...
- Federal Grant Award Summary J. David Gladstone Institutes received a $1.46 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) to conduct research on inhibitory neuron dysfunction in Alzheimer's disease models. The award, effective August 1, 2025 through July 31, 2027, supports the development and implementation of innovative methodologies to monitor and manipulate parvalbumin (PVALB) and somatostatin (SST) inhibitory interneuron...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded The Washington University a Project Grant totaling $1,851,569 under the Aging Research program (CFDA 93.866) for the period June 1, 2025, through March 31, 2030. This research initiative, titled "First In Last Out: How Development Informs Neurodegeneration," investigates the biological mechanisms linking early brain development to late-life Alzheimer's disease (AD) pathology. The project aims to empirically...
- Federal Project Grant Award Summary The National Institute on Aging awarded the University of Virginia a $522,167 Project Grant, effective August 1, 2025, through May 31, 2030, under the Aging Research program (CFDA 93.866). The award supports research investigating mechanisms of ribosomal DNA (rDNA) instability during aging, with the objective of understanding how genomic instability contributes to the aging process. The research focuses on characterizing the roles of the FOB1 protein and...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Tufts University School of Medicine a $470,000 Project Grant under the Aging Research program (CFDA 93.866) on February 1, 2026, with a completion date of January 31, 2028. This grant funds research titled "Elucidating the Interplay Between AD Genetic Variants Using Human iPSC-Derived Brain Cells," which investigates the genetic mechanisms underlying Alzheimer's disease (AD). Given that AD has an estimated...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $506,000 in project grant funding to the Scripps Research Institute under the Aging Research program (CFDA 93.866) on August 15, 2025, with a completion date of July 31, 2027. The project, "Engineering Synthetic Biomolecular Condensates for Targeted Autophagy Modulation," will deliver foundational research and development of a novel biomolecular condensate (BMC)-based scientific tool designed to advance...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded the Broad Institute of MIT and Harvard a Project Grant of $610,836 under the Aging Research program (CFDA 93.866) for the period September 1, 2025 through May 31, 2030. This award supports research on genetic dissection of mitonuclear interactions in aging and neurodegenerative disease. The research will leverage two technological advances—mitochondrial DNA (mtDNA) editing using DDCBE base editors and biobank-scale...
- Federal Grant Award Summary The J. David Gladstone Institutes received a $630,496 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) for the period June 1, 2025, through March 31, 2030. The award funds research investigating proteostasis dysfunction, neuroinflammation, and neurodegeneration in frontotemporal dementia (FTD) caused by GRN (granulin) haploinsufficiency. The research will examine how GRN deficiency impairs the autophagy/lysosomal...
The Buck Institute for Research on Aging received $809,486 in Project Grant funding from the National Institute on Aging (CFDA 93.866 – Aging Research program) beginning February 1, 2026, through January 31, 2031. The award supports comprehensive biomedical research investigating the role of oxidation resistance 1 (OXR1) and retromer proteins in brain aging and Alzheimer's disease and related dementias (ADRD). The research leverages multiple model systems, including Drosophila melanogaster (fruit fly) and human-induced pluripotent stem cell (iPSC)-derived neurodegenerative disease models, to elucidate mechanisms by which OXR1 enhances retromer function to slow aging and neurodegeneration. The deliverables include scientific investigation of specific retromer components and their protective mechanisms against age-related neurodegeneration, with focus on downstream pathways including endocytic recycling, synaptic homeostasis, and lipid metabolism. The research integrates proteomics data from over 2,000 Alzheimer's disease patients from the Accelerating Medicines Program–Alzheimer's Disease Network to establish human relevance. This five-year project aims to advance understanding of genetic and dietary risk factors for late-onset Alzheimer's disease and support development of potential therapeutic interventions targeting the OXR1-retromer pathway.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $809.5k | 1/21/26 |